|
Issue No.
4
| February 01, 2013
|
|
|
Subscribe to the AIDSinfo At-a-Glance e-newsletter to receive regular updates on the latest in HIV/AIDS treatment, prevention, and research. |
![Globe of the earth](https://webarchive.library.unt.edu/web/20130218181443im_/http://aidsinfo.nih.gov/images/ataGlance/1_globe_image.jpg) |
|
![](https://webarchive.library.unt.edu/web/20130218181443im_/http://aidsinfo.nih.gov/images/ataGlance/1_pixel_gray.gif) |
|
FDA Updates Complera Labeling with New Indication and Clinical Trial Information
“On January 25, 2013, FDA approved changes to the Complera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) package insert. The major changes include restricting the indication to treatment-naïve adult patients with HIV-1 RNA less than or equal to 100,000 copies/mL, updating the package insert with the 96 week results from the Phase 3 trials and adding a new Contraindication and new Warning and Precaution for hepatotoxicity.”
More information is available:
New Publications Available from CDC
The Centers for Disease Control and Prevention (CDC) recently issued the following three publications:
|
|
|
|
|
![ClinicalTrials.gov Info](https://webarchive.library.unt.edu/web/20130218181443im_/http://aidsinfo.nih.gov/images/ataGlance/1_rsb_clin_tri_hd.gif)
![Subscribe Info](https://webarchive.library.unt.edu/web/20130218181443im_/http://aidsinfo.nih.gov/images/ataGlance/1_rsb_sub_hd.gif)
![Contact AIDSinfo](https://webarchive.library.unt.edu/web/20130218181443im_/http://aidsinfo.nih.gov/images/ataGlance/1_rsb_cont_aids_hd.gif)
|